# What the RED-CABG trial found about acadesine in heart surgery

- Article ID: research-030
- Product: AICAR (aicar-427)
- Canonical page: https://heritagebiolabs.com/research-library/articles/030-what-the-red-cabg-trial-found-about-acadesine-in-heart-surgery
- Product collection: https://heritagebiolabs.com/research-library/products/aicar
- Product page: https://heritagebiolabs.com/product/aicar-427
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2012

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides consist of short chains of amino acids joined by peptide bonds and can serve as signals in the body. AICAR, also called acadesine, is a ribonucleoside. It has been studied for its effects on cellular metabolism and adenosine-related processes. For the specific question of outcomes around coronary bypass surgery, the older RED-CABG study provides randomized human evidence. [1]

During coronary artery bypass grafting, surgeons create a new route for blood to reach heart muscle beyond a blocked artery. The trial tested whether adding acadesine around the operation would reduce important complications in people undergoing surgery with a heart-lung machine. Participants were assigned to acadesine or placebo. The main outcome combined death from any cause, nonfatal stroke and severe left ventricular dysfunction that required mechanical support. Combining these outcomes allowed investigators to assess the intervention against events that would matter directly to patients. [1]

A planned analysis indicated a very low chance of demonstrating benefit if the trial continued as designed. The study stopped after randomizing 3,080 participants. Among the participants included in the primary analysis, the combined outcome occurred in about five percent in each group. The published analysis found no difference in the key secondary outcomes measured. [1]

This is human evidence for a particular surgical setting, formulation and set of outcomes. It cannot decide whether AICAR changes an enzyme response in isolated muscle or affects an unrelated disease. It does show the value of comparing a mechanistic idea against patient outcomes. Even when adenosine biology gives researchers a reason to test a compound during surgery, the clinical result depends on what actually happened to participants. [1]

## Sources

1. Mark F. Newman et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA (publication 2012-07-11). <https://pubmed.ncbi.nlm.nih.gov/22782417/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 006 - AICAR.docx; article 30; content SHA-256 f308c94deff4cc8609d77dab635d606b0d9c2d1b848602bc5a27b409dca44694.
